Biovail Articles
Shareholders give green light to Biovail and Valeant merger, former chairman says merger 'doomed'
28 September 2010
Valeant and Biovail agree “$.3.2 billion” reverse merger to create a $1.75 billion sales group
22 June 2010
Cortex sells selected Ampakine compounds and rights to respiratory depression indication to Biovail for up to $25 million
29 March 2010
Showing 1-4 of 4 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
